No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ITCI240816C85000
- 0.95
- +0.20+26.67%
15min DelayTrading Jul 23 11:15 ET
0.95High0.70Low
0.70Open0.75Pre Close7 Volume551 Open Interest85.00Strike Price615.00Turnover41.90%IV9.85%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.95Extrinsic Value100Contract SizeAmericanOptions Type0.2533Delta0.0376Gamma62.59Leverage Ratio-0.0584Theta0.0125Rho15.86Eff Leverage0.0650Vega
Intraday
- 5D
- Daily
News
Needham Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Raises Target Price to $100
NVIDIA To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday
Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $100
Express News | Intra-Cellular Therapies Inc : Needham Raises Target Price to $100 From $94
Analysts Expect Breakeven For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Before Long
Morgan Stanley Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $92
Comments
🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies(ITCI.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$Hutchmed (China)(HCM.US$ Phase 3
$Viracta Therapeutics(VIRX.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Marinus Pharmaceuticals(MRNS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3 ...
$Intra-Cellular Therapies(ITCI.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$Hutchmed (China)(HCM.US$ Phase 3
$Viracta Therapeutics(VIRX.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Marinus Pharmaceuticals(MRNS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3 ...
16
Intra-Cellular Therapies is nearing breakeven, contingent on maintaining a 57% annual growth rate. Its lack of debt, unusual for a pharma company, reduces investment risk.
2
🎯 Ph 3 readouts in Q1 2024...
$Pfizer(PFE.US$ Phase 3
$Palatin Technologies(PTN.US$ Phase 3
$Annovis Bio(ANVS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$ $Novocure(NVCR.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3
$Sellas Life Sciences(SLS.US$...
$Pfizer(PFE.US$ Phase 3
$Palatin Technologies(PTN.US$ Phase 3
$Annovis Bio(ANVS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$ $Novocure(NVCR.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3
$Sellas Life Sciences(SLS.US$...
16
The market seems optimistic about Intra-Cellular Therapies, Inc. given its strong revenue growth and share price momentum. It's recommended to take a closer look at this stock.
Read more